Kanada - enska - Health Canada

pharmel inc - leflunomide - tablet - 10mg - leflunomide 10mg - disease-modifying antirheumatic agents

Kanada - enska - Health Canada

pharmel inc - leflunomide - tablet - 20mg - leflunomide 20mg - disease-modifying antirheumatic agents

Kanada - enska - Health Canada

dominion pharmacal - leflunomide - tablet - 10mg - leflunomide 10mg - disease-modifying antirheumatic agents

Kanada - enska - Health Canada

dominion pharmacal - leflunomide - tablet - 20mg - leflunomide 20mg - disease-modifying antirheumatic agents

Kanada - enska - Health Canada

mylan pharmaceuticals ulc - leflunomide - tablet - 10mg - leflunomide 10mg - disease-modifying antirheumatic agents

Kanada - enska - Health Canada

mylan pharmaceuticals ulc - leflunomide - tablet - 20mg - leflunomide 20mg - disease-modifying antirheumatic agents

Kanada - enska - Health Canada

nu-pharm inc - leflunomide - tablet - 10mg - leflunomide 10mg - disease-modifying antirheumatic agents

Kanada - enska - Health Canada

nu-pharm inc - leflunomide - tablet - 20mg - leflunomide 20mg - disease-modifying antirheumatic agents

Bandaríkin - enska - NLM (National Library of Medicine)

alembic pharmaceuticals inc. - leflunomide (unii: g162gk9u4w) (leflunomide - unii:g162gk9u4w) - leflunomide 10 mg - leflunomide tablets usp are indicated for the treatment of adults with active rheumatoid arthritis (ra).  leflunomide is contraindicated in: ·            pregnant women. leflunomide may cause fetal harm. if a woman becomes pregnant while taking this drug, stop leflunomide, apprise the patient of the potential hazard to the fetus, and begin a drug elimination procedure [see warnings and precautions (5.1 and 5.3) and use in specific populations (8.1)].   ·            patients with severe hepatic impairment [see warnings and precautions (5.2)]. ·            patients with known hypersensitivity to leflunomide or any of the other components of leflunomide. known reactions include anaphylaxis [see adverse reactions (6.1)]. ·             patients being treated with teriflunomide [see drug interactions (7)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to leflunomide during pregnancy. health care providers and patients are encouraged to report pr

Bandaríkin - enska - NLM (National Library of Medicine)

alembic pharmaceuticals limited - leflunomide (unii: g162gk9u4w) (leflunomide - unii:g162gk9u4w) - leflunomide 10 mg - leflunomide tablets usp are indicated for the treatment of adults with active rheumatoid arthritis (ra).  leflunomide is contraindicated in: ·            pregnant women. leflunomide may cause fetal harm. if a woman becomes pregnant while taking this drug, stop leflunomide, apprise the patient of the potential hazard to the fetus, and begin a drug elimination procedure [see warnings and precautions (5.1 and 5.3) and use in specific populations (8.1)].   ·            patients with severe hepatic impairment [see warnings and precautions (5.2)]. ·            patients with known hypersensitivity to leflunomide or any of the other components of leflunomide. known reactions include anaphylaxis [see adverse reactions (6.1)]. ·             patients being treated with teriflunomide [see drug interactions (7)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to leflunomide during pregnancy. health care providers and patients are encouraged to report pr